1 / 3

Questions to the Committee

Questions to the Committee. 1. It is proposed to collect DNA samples from all participants in clinical trials. What issues or barriers should be addressed to facilitate routine collection of DNA samples?

seanna
Télécharger la présentation

Questions to the Committee

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Questions to the Committee 1. It is proposed to collect DNA samples from all participants in clinical trials. • What issues or barriers should be addressed to facilitate routine collection of DNA samples? • When (under what circumstances, to what degree), should DNA be collected during drug development for use in exploratory analysis?

  2. Questions to the Committee 2. A decision tree depicting the integration of pharmacogenetic studies into the drug development process is proposed. • What comments and/or recommendations does the committee have on the scientific rationale and thought process embodied in the proposed decision tree?

  3. Questions to the Committee 3. Different study types for clinical pharmacogenetic studies are proposed. • What comments and/or recommendations does the committee have on the design of clinical pharmacogenetic studies and their proposed impact on subsequent clinical trials?

More Related